PER-057-00已完成未知
TREATMENT OF LESHMANIASIS CUTANEA PERUANA WITH PENTAMIDINE ISETIONATE (WR 179745) USING MEGLUMIN ANTIMONIATE AS A POSITIVE CONTROL: A PHASE III B STUDY
IVERSIDAD PERUANA CAYETANO HEREDIA,0 个研究点目标入组 0 人开始时间: 2000年10月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Be able to give written consent. Written consent will be signed as soon as the prospective volunteer shows a reasonable understanding of the study, its risks and benefits and its role, after the principal investigator or designated study member has provided a full explanation. The volunteer can ask any question. The written consent will be in Spanish or Quechua, whatever the language the volunteer can understand. The volunteer can keep a copy of the consent.
- •Availability to meet the study schedule
- •Good health
- •Age: 18-60 years of age
- •Parasitological diagnosis: having cutaneous leishmaniasis parasitologically proven in the lesion.
排除标准
- •Intolerance to the drug. History of known or suspected hypersensitivity or idiosyncratic reactions to pentamidine Pentostam® or Pentacarianato®, meglumine antimonate, Glucantime®, sodium stibogluconate or Pentostam®
- •Previous use of antileishmanial drugs
- •Current use of nephrotoxic drugs, which induce pancreatitis or hypoglycemics on a routine basis, list presented in Appendix 1.
- •Previous history of leishmaniasis confirmed on the basis of a clinically compatible history (due to a previous scar)
- •Potential for follow-up: that can not be followed for 8 months.
- •Concomitant medical problems: significant medical problems of the kidney, pancreas or impaired glucose control as determined by laboratory and background studies. Volunteers in whom these normal laboratory values do not exceed more than 25% are not automatically excluded. These volunteers will be evaluated based on their background, and both physical and laboratory values.
- •Any acute medical or psychiatric condition that may increase the risks associated with participation in the study or interfere with the interpretation of study results in the opinion of the treating researcher: patients with systemic disease, such as TB diagnosed by pulmonary radiography or presence of bacilli (acid fast) in colored sputum smears.
- •Pregnancy or lactation: any woman who is pregnant or breastfeeding will not be able to enter the clinical study. Women of childbearing age and capacity will not be able to participate in the study unless they agree to avoid sexual activity during the drug treatment period, plus 2 weeks.
- •Evidence of mucosal involvement in the oropharynx.
研究者
相似试验
已完成
不适用
APER-012-99IVERSIDAD PERUANA CAYETANO HEREDIA,
招募中
2 期
Treatment of cutaneous leishmaniasis with thymol loaded chitosan gelIRCT20180526039848N1Mashhad University of Medical Sciences50
已完成
2 期
Evaluation of the treatment of cutaneous leishmaniasis with Epigallocatechin Gallatecutaneous leishmaniasis.Cutaneous leishmaniasisB55.1IRCT20180526039848N2Mashhad University of Medical Sciences40
已完成
早期 1 期
herbal medicine in cutaneous leishmaniasiseishmaniasis.Cutaneous leishmaniasisIRCT2013011512143N1Shiraz University of Medical Sciences88
已完成
3 期
A clinical trial to assess the safety and effect of heat therapy in comparison to standard intra-lesional sodium stibogluconate for cutaneous leishmaniasiscutaneous leishmaniasisSkin - Dermatological conditionsInfection - Other infectious diseasesACTRN12614001288617niversity of Colombo194